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Background. Recent studies uggest that the therapeutic et&& 
cd conwtbq enzyme inhibitors invalve “001 only the renti- 
angiotemin and pmrtagtaodin qstaw but 111~0 the sympathetic 
wtetem. 
Methods. Twelve byprtrnsive and 20 normOtensiw men were 
studied aftw 3 S.day hosjtal s(ays during which they nmmmod a 
IO-mEq sodium dtet and received captopril (25 me; twice daily) (lr 
pkwbo in a daubk.blii avswwc sludy. 
Results. Csptoprtt decremed neum~pttde Y ,p < 0.05) and 
angketi II (p < 0.01) and tncreawd tsoprctere”ot.sltnutated 
Angiotensin-converting enzyme inhibitors are widely used 
for the treatment of hypertension and heart failure (I). 
Although the eKects of these agents on the rain-nngiotensin 
system are well described (2). studies examining their effects 
on tbe sympathetic nervous system present a more complex 
picture. Angiotensin-converting enzyme inhibition de- 
creates attgiotensin II (which augments norepinephrine re- 
lease and responsiveness) and increases prostadandin E, 
(which inhibits norepinephrine release) (3-7). Both short- 
and long-term angiotensin-converting enzyme inhibition dur- 
ing restricted sodium intake increases plasma norepineph- 
rine (E-10). whereas there is no change in norepi&ph& 
durinn unrestricted sodium intake (8.10.1 Il. Interestinelv. _. 
regardless of sodium intake or no&nephrine levels, beta- 
adrenergic receptor function may increase with both short- 
and long-term angiotensin-converting enzyme inhibition 
(9.12). 
cyclic adenorine monaphospLatc WIP) in lyqbeqtes (p < 
O.OJ), plasm;. no~pieephrioe (p < 0.021, wtimt (p < 0.w and 
renin (p < 0.001) in b&b brprtcnstvc sub@. 
Hypprtrnsive rub&is bad 811 =wt= 
density (p 4 0.02) aod a gmter Kerr ia d&t&c b&xl 
p+ersure mmpared rttb owmotetive vdbjfzts (p C B.02). 
ConcluGms. Tb rerutts d this study 
term therapeuttt clffxts Oc ceptoprtt may imvtve 
changes in key 
Tbf5c findings. 
blcnascd nwep 
patibte with the obscrvatkm of 
decrewd periphtrrl &stance 
mnvcrttng enzyme bddbitioo. 
U *a COU Ce4.diol1993,.21:177-81, 
In addition to norepinephrine and beta-adrenergic recep 
tow several other components of the sympathetic nervuus 
system have important roles in modulating cardiovascular 
activity. Neuropeptide Y is a 36-amine acid peptide stored 
with norepinephrine in sympathetic nerves and the adrenal 
medulla (13,14). Neuropeptide Y has diverse sympathetic 
effects. acting both antagonistically and synergistically oo 
various adrenergic-mediated cardiovascular iunctions. Neu- 
ropeptide Y potentiates the vascular effects of norepineph- 
rine and angiotensin II (l5,16) yet inhibits adrenergically 
stimulated cyclic adenosine monophosphate (AMP) produc- 
tion in atrial cells (17). Additionally, neuropeptide Y pa- 
sews direct vasoconstrictor properties independent of ad- 
renergic activation (14.15). Animal studies (18) suggest hat 
captopril may increase plasma llzumpeptidr Y. 
Cotticosteroids potentiate the zffect of adrenergic- 
mediated stimulation of several physiologic systems by 
oromotine the formation of the high atlinitv caunlcd state of 
;he beta-adrenergic receptor (1<20). Th&e 11 cotiicting 
evidence (21,22) on the effects of angiotensin II on plasma 
coflisol. 
This study sought to further delineate the short-term 
effects of angiotensin-converting enzyme inhibition on the 
sympathetic and renin-angiotensin systems in both hypertetr 
s&and normotensive subjects. We chose to examine the 
effects of angiotensincauverting enzyme inhibition during 
sodium restriction, reawning that any potential effects 
would be more marked in a setting where the renin- propranolol. Incubations were terminated by filtration with 
angiotensin system was activated. Thus, we placed all sub- 20 ml ofTris wash buffer. Beta-adrenergic receptor density 
jects on an isocaloric diet providing 10 mEq of sodium and (Bmax) was calculated by using a nonlinear regression 
100 of mEq potassium daily. This design enabled us to receptor-binding software program (GraphPad). 
contrast two different states: an activated renin-anaiotensin Lymphocyte beta,-adrenergic receptor sensitivity was 
system (placebo and low salt) and a high rain wilhblocked 
aogiotensin system (captopril and low salt). We measured 
several markers of sympathetic activity, including nemopep- 
tide Y, norepinephrine. beta-adrenergic receptors and corti- 
sol. Special attention was given to evaluating the potential 
contributions of neuropeptide Y and cortisol in earlier re- 
ports on the effects of angiotensin-converting enzyme inhi- 
bition. 
Methods 
adrenergic receptor density and sensitivity, plasma norepi- 
category on both screening occasions were enrolled. The 
Study group. Volunteers were located through cammu- 
nity blood pressure screening or word of mouth referral. 
nephrine, epinephrine, neuropeptide Y, cortisol, renin and 
Twelve unmedicated hypertensive men (blood pressure 
protocol was approved by the University of California, San 
>140190 mm Hg at screening; and 20 normotensive men 
angiotensin II. Lymphocytes are commonly used as models 
(blood pressure <14ONO mm Hg at screening) were studied 
Diego Institutional Review Board. 
after providing written ioformed consent. Blood pressure 
of beta-adrener.eic receptors because lymphocvte beta,- 
diagnoses were made on the basis of three blood pressure 
Protocol. Subjects were evaluated after two separate 
meawrements on two screening occasions approximately I 
week apart. OnIv those who remained in the same diaanostic 
T-day hospital stays in a randomized double-blind crossover 
design, with subjects receiving either placebo or captopril 
(25 mg twice daily). On the night before the final day of each 
admission, each subject had a heparin lock placed in a 
forearm vein. The next morning while he was at rest, blood 
was sampled for the determination lymphocyte beta,- 
d&m&d k whole cells by quantifying cyclic AMP accos 
mulation after a tmin incubation with 10 pmoliliter of 
isoproterenol. Lymphocytes were suspended in cold Dul- 
becco’s modified Eagle’s medium. Incubations in quadropli. 
cate were begun by adding 0.1 ml of approximately 5 x lo5 
cold cells to 0.9 ml of 37’C Dulbecco’s modified Eagle’s 
medium containing 100 pmoliIiter of isobutylmethylxanthine 
and 100 pmo!iIiter of RoZC-1724 to inhibit cyclic nucleotide 
phasphodiesterase activity. Half of the tubes also contained 
1O-5 moUIiter of isoproterenol. After 2 min, the reactions 
were terminated by centrifuging at 11,000 rpm, aspirating the 
supematant, resuspending the pellet in 0.1 ml of 50 mmoll 
liter of sodium acetate containing 0.2 mmolJliter of isobutyl- 
methvlxanthine loH 4.0) and olacine the tubes in a bvilina 
wate; bath for aiproxi&ately’S min. The tubes were then 
frozen and later assayed for cyclic AMP. 
commercial radioimmunoassay techniques. 
t&mdin~ i, receptor sensi&ty WA similarly measured 
St&ties. Data were analyzed by two-way (diagnosis x 
after stimulation with 20 ~ollliter of prostaglandin E,. 
drug) repeated meawes analysis of variance (BMDP Statis- 
Blwd samples were collected on ice and separated in B 
tical Software). 
reftigemted centrifuge. Plasma was Stored at -80°C until 
assay. Miasma catecholamines were analyzed by radioeozy 
matic assay, with an assay coefficient of variation <IO% for 
norepinephrine and <12% for epinephrine (25). Angiutensin 
II and neuropeptide Y were coUeeted and assayed according 
In addition to betaradrenergic receptors, lymphocytes 
contain prostaglandin E, receptors. Beta*-adrenergic and 
prostaglandin E, receptors share the same postreceptor G, 
to previously published methods (Z&27). Cortisol (Diagnos- 
remdatorv protein and adenylate cvclase systems. Pros- 
tic Products, Inc.) and rain (INCSTAR) were assayed by 
. 
adrenergic receptors correlate with beta-adrenergic recep 
tars in the heart and bums (1223.241. Three seated blood 
pressure measurements were thei &ken over 3 min; the 
average of these was taken as the blood pressure at rest. 
Testing took place at the same time of day during each 
hospital admission (approximately 900 AM). The lion! 25-mg 
dose of captopril was given at approximately &Oil AM an the 
morning of testing. 
Assays. Lymphocyte isolation and receptor assays were 
conducted according to previously published methods (9). 
Briefly, lymphocyte membranes were sbspzadc?. i:: 
50 mallliter of Tris buffer, 8 mmoffliter of magnesium chlo- 
ride and 0.5 mmollliter ethylenediaminetetraaeetic acid 
(BDTA) at pH 7.5. Saturation mdioligand binding isotherms 
were performed using iodine-125iodopindotol at six eoncen- 
trations. ranging from 10 to 320 pmollliter for I h at 37%. 
Specific binding was determined by using 10 CmaliIiter of 
RS.UltS 
Hypertensive and normotensive subjects were similar in 
age, weight and sodium excretion Qble I). 
All date am! statistics are preserwed in Table 2. Compared 
with placebo, captopril increased isaproterenol-stim;lated 
cvclic AMP production, norepinephrine, cortisol and renin 
ii both grouts. In response td cz&pril, only the hypeflen- 
sive subjects had an increased beta-adrenergic receptor 
&wi!v. Diastolic blood pressure decreased more substan- 
tidy in hypertensive subjects than in normotensive sub- 
iects. Both aneiotensin II and neurooeoride Y decreased 
with captopril-Captopd did not aIt.& ‘heart rate, plasma 
epinephrine or prostagkwdin El-stimulated cyclic AMP pro- 
duction. 
The blood pressure values in Tables I and 2 show that 
after the S-day hospital stay, our “hypertensive” subjects 
were now in the normotensive range. This decrease in blood 
pressure with hospitalization is common (28). The consis- 
tency of the blood presrure values during our repeated 
screenings leaves no doubt, however, as to the elevated 
blood pressure values in our hypertensive patients (mean 
149196 mm Hs). 
Discussion 
Early studies (2) presented a simpler view of the efiec!~ 
of angiotensin-converting enzyme inhibitors, asc:ibing 
their therqxutic elfects primarily to a decrease in angio- 
tensin II-mediated vasoconslriction aad an increase in 
prostaglandin-mediated vasodilation. Later studies de- 
scribed potentially important changes in the sympathetic 
nervous system as well. We have replicated and extended 
these observations. In addition to the increase in plasma 
norepinephrine and beta-adrenergic receptor sensilivity (S- 
10.12). our study suggests that short-term captopril adxis- 
iktration during sodium restriction leads to dare& neu- 
ropeptide Y and increased cortisol. The captopril-related 
decrease in neuropeptide Y replicates findings in an isolated 
report (181 under conditions of unrestricted s&km in’%k in 
animals. Hypertensive subjects also had increased beta- 
adrenergic receptor density and a greater decrease in dia- 
stolic blood pressure than did nomwtensive subjects. 
Decreax in nmrquptide Y. Although the concurrent 
decrease m ncuropeptide Y and incxase in norepinepkine is 
surprising, it may help tinther explain the therapeutic &Us 
of captopril. For example, neumwptide Y is a potent 
vasoconstrictor and is elevated in hyprteztsion (29). it also 
enhances norepinephrine-mediated vasoccastriction (15,16). 
The decrease in neurooeotide Y could thus contribute in 
several ways to rhe hyb&eive effects of captopril. Addi- 
tionally, captopril improves cardiac function and decreases 
peripheral resistance in congestive heart failure (30). Neu- 
mpeptide Y and norepineph&e are increased in congestive 
heart failure (311. Unlike noreoineohtine, neurowMide Y 
exerts predominantly negative~chr&wtrapic and &tropic 
effects. Neuropeptide Y-induced vawaxtstrictioa of OXG- 
nary arteries leads to an ischemic reduction in myocardial 
performance (32). Neuropepride Y also inhibits beta- 
adrenereic recemor activation of mvcardial cells (17). Hv- 
pothetic&y. d&eased neumpeptide Y combined with &- 
creased norepinepbrine and beta-adrenergic receptors after 
the administration of captopril could thus contribute to the 
observations of increased cardiac output and decreased 
peripheral resistance in congestive heart failure (12,30) and 
related models of cardiovascular disease (33). Other than 
this study, there are few or no data on the effects ofcaptopril 
on neuropeptide Y in humans and thus this observation 
merits replication. 
Regarding the nature of the mechanism or mechanisms 
!xtder!ying the decrease in neuropeptide Y, ua!ike ttorepi- 
T&k 2. Effects of Short-Term CaPtomil Adminis!n!ion During Sodium Restriction 
nephrine, neuropeptide Y is not subject to reuptake mecha- 
nisms. This observation suggests that the decrease in neu- 
ropeptide Y results from either an increase in its clearance 
rate or a decrease in its release rate. One study (18) in the 
guinea pig suggests that captopril may reduce ncuropeptide 
Y through a nonangiotensin II-related mechanism. A recent 
observation (34) suggests that corticosteroids may reduce 
neuropeptide Y. 
We used venous narepinephrine and neurapeptide Y as 
indexes of sympathetic nervous system activity. Although 
venous levels are perhaps a less precise index than arterial 
levels, previous studies have reported good correlations 
between venous norapinephsine levels and direct monitoring 
of sympathetic nerves (35. for review). 
Increase in norepinaphrlne and cortisol. In addition to 
neuropeptide Y, norepinephrine and cortisol affect beta- 
adrenergic receptor-mediated activity and both were in- 
creased in our subjects. Although lymphocyte beta,- 
adrencrgic receptors may be regulated primarily by a change 
in blood pressure and not by cawholamines (361, an in- 
crease in norapinephrine tends to desensitize adrcncrgic 
receptors. In contrast, cortisol inhibits extraneuronal uptake 
of norepinephrine and may sensitize beta-adrenergic recap- 
tars by promotmg coupling of the receptor G, regulatory- 
binding protein complex (1920). The absence of an accom- 
panying change in prostaglandin E, receptor sensitivity, 
which utilizes the same postreceptor G, regulatory- 
adenylate cyclase system, supports the notion of an increase 
in beta-receptor 0, coupling rather than a change in G, or 
adenylate cyclase levels. 
Conclusions. These data replicate and extend previous 
studies that examined the effects of angiotensin-converting 
enzyme inhibition on sympathetic function and daggest 
that short-term captopril administration during sodium 
restriction leads to potentially important compensatory 
changes in several components of the sympathetic nervous 
system. These findings, such as decreased neuropeptide 
Y combined with increased norepinephrine and beta- 
adrenergic receptors, are compatible with the observa- 
tion of increased cardiac output and decreased peripheral 
resistance after short-term angiotensin-converting enzyme 
inhibition. 
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